Critical Comparison: Kyntra Bio (NASDAQ:KYNB) & TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX) and Kyntra Bio (NASDAQ:KYNB) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Profitability

This table compares TG Therapeutics and Kyntra Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Kyntra Bio	2,199.13%	N/A	-47.27%

Institutional and Insider Ownership

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares TG Therapeutics and Kyntra Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29 million	13.40	$447.18 million	$2.74	19.70
Kyntra Bio	$6.44 million	3.05	$183.45 million	$45.30	0.11

TG Therapeutics has higher revenue and earnings than Kyntra Bio. Kyntra Bio is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for TG Therapeutics and Kyntra Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1	2	6	0	2.56
Kyntra Bio	2	0	5	0	2.43

TG Therapeutics currently has a consensus price target of $63.00, suggesting a potential upside of 16.73%. Kyntra Bio has a consensus price target of $36.80, suggesting a potential upside of 658.76%. Given Kyntra Bio’s higher possible upside, analysts plainly believe Kyntra Bio is more favorable than TG Therapeutics.

Risk & Volatility

TG Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Summary

TG Therapeutics beats Kyntra Bio on 10 of the 14 factors compared between the two stocks.

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.